Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages (Q38184922)

From Wikidata

Jump to navigation Jump to search

scientific article published on 04 February 2014

Language	Label	Description	Also known as
English	Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages	scientific article published on 04 February 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

0 references

Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

enzyme replacement therapy

0 references

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Saskia M Rombach

1

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Bouwien E Smid

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Gabor E Linthorst

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Marcel G W Dijkgraaf

4

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Carla E M Hollak

5

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

publication date

4 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Journal of Inherited Metabolic Disease

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

341-352

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Fabry disease: overall effects of agalsidase alfa treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Fabry disease in children: agalsidase-beta enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Quantitative analysis of cerebral vasculopathy in patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Natural history of Fabry disease in females in the Fabry Outcome Survey.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Agalsidase alfa slows the decline in renal function in patients with Fabry disease.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Fabry's disease presenting with stroke

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Clinical presentation in female patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Evaluation of the quality of prognosis studies in systematic reviews

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--the Fabry Outcome Survey.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Onset and progression of the Anderson-Fabry disease related cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Cardiac manifestations of Anderson-Fabry disease in children and adolescents

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Fabry's Disease: Alpha-Galactosidase Deficiency

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Cerebrovascular complications of Fabry's disease

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Enzyme replacement therapy improves cardiac features and severity of Fabry disease

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Cardiovascular events in patients with fabry disease natural history data from the fabry registry

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Safety of agalsidase alfa in patients with Fabry disease under 7 years.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

The natural history of left ventricular systolic function in Anderson-Fabry disease.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Agalsidase benefits renal histology in young patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Agalsidase alfa and kidney dysfunction in Fabry disease.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-014-9677-8

21 January 2018

Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiproteinuric Therapy and Fabry Nephropathy: Sustained Reduction of Proteinuria in Patients Receiving Enzyme Replacement Therapy with Agalsidase-beta

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzyme replacement therapy for Anderson-Fabry disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An Atypical Variant of Fabry's Disease in Men with Left Ventricular Hypertrophy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzymatic Defect in Fabry's Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzyme replacement therapy with agalsidase alfa in children with Fabry disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzyme replacement therapy for Anderson-Fabry disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzyme replacement therapy for Fabry disease: some answers but more questions

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical benefit of enzyme replacement therapy in Fabry disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence and Clinical Significance of Cardiac Arrhythmia in Anderson-Fabry Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Brain MRI findings in patients with Fabry disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Right ventricular involvement in patients with Fabry's disease and the effect of enzyme replacement therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzyme replacement therapy and renal function in 201 patients with Fabry disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24492980

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10545-014-9677-8

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38184922&oldid=2201377614"